Table 3. Diagnostic Outcomes of Unmatched and Propensity Score–Matched Groups.
Outcome | No. (%) | |||||||
---|---|---|---|---|---|---|---|---|
Unmatched participants | Propensity score–matched (1:1) participants | |||||||
Total (n = 67 683), No. (%) | Received cimetropium bromide (n = 28 280), No. (%) | Did not receive cimetropium bromide (n = 39 403), No. (%) | P valuea | Total (n = 41 670), No. (%) | Received cimetropium bromide (n = 20 835), No. (%) | Did not receive cimetropium bromide (n = 20 835), No. (%) | P valuea | |
Total gastric neoplasms | 160 (0.24) | 87 (0.31) | 73 (0.19) | .001 | 102 (0.24) | 63 (0.30) | 39 (0.19) | .02 |
Dysplasia | 85 (0.13) | 44 (0.16) | 41 (0.10) | .06 | 52 (0.12) | 32 (0.15) | 20 (0.10) | .10 |
Early cancer | 61 (0.09) | 36 (0.13) | 25 (0.06) | .006 | 40 (0.10) | 25 (0.12) | 15 (0.07) | .11 |
Advanced cancer | 10 (0.01) | 6 (0.02) | 4 (0.01) | .34 | 7 (0.02) | 5 (0.02) | 2 (0.01) | .26 |
Lymphoma | 3 (0.004) | 1 (0.004) | 2 (0.01) | >.99 | 3 (0.01) | 1 (0.005) | 2 (0.01) | .56 |
Neuroendocrine tumor | 1 (0.001) | 0 | 1 (0.003) | >.99 | 0 | 0 | 0 | NA |
Dysplasia and early cancer | 146 (0.22) | 80 (0.28) | 66 (0.17) | .002 | 92 (0.22) | 57 (0.27) | 35 (0.17) | .02 |
Small gastric neoplasmsb | 56 (0.08) | 35 (0.12) | 21 (0.05) | .002 | 35 (0.08) | 24 (0.12) | 11 (0.05) | .03 |
Dysplasia | 42 (0.06) | 26 (0.09) | 16 (0.04) | .008 | 26 (0.06) | 18 (0.09) | 8 (0.04) | .05 |
Early cancer | 14 (0.02) | 9 (0.03) | 5 (0.01) | .09 | 9 (0.02) | 6 (0.03) | 3 (0.01) | .32 |
Location | ||||||||
Cardia and fundus | 5 (0.01) | 2 (0.01) | 3 (0.01) | >.99 | 4 (0.01) | 2 (0.01) | 2 (0.01) | >.99 |
Body | 72 (0.11) | 44 (0.16) | 28 (0.07) | .001 | 49 (0.12) | 34 (0.16) | 15 (0.07) | .007 |
Antrum | 82 (0.12) | 40 (0.14) | 42 (0.11) | .20 | 49 (0.12) | 27 (0.13) | 22 (0.11) | .48 |
Abbreviation: NA, not available.
P values were determined using an χ2 test or a Fisher exact test for unmatched data and a McNemar test for matched data.
Neoplasms <1 cm in diameter.